Bhuiyan Sakil, Siddiqui Raheel S, Zirkiyeva Milana, Agladze Mariam, Bashir Tayyaba
Internal Medicine, Icahn School of Medicine at Mount Sinai, Queens Hospital Center, New York City, USA.
Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, Queens Hospital Center, New York City, USA.
Cureus. 2021 May 20;13(5):e15136. doi: 10.7759/cureus.15136.
Small cell lung cancer (SCLC) accounts for less than 15% of the cases of lung cancer. Epidermal growth factor receptor (EGFR) mutations are rarely reported in association with SCLC. EGFR tyrosine kinase inhibitors (TKI) are approved as the first-line therapy for metastatic non-small cell lung cancer (NSCLC). The clinical effect of EGFR mutations and its response to osimertinib are unknown in SCLC. We report a case of EGFR-positive metastatic SCLC in a 63-year-old female who was treated with the third-generation TKI, osimertinib.
小细胞肺癌（SCLC）占肺癌病例的比例不到15%。表皮生长因子受体（EGFR）突变与SCLC相关的报道很少。EGFR酪氨酸激酶抑制剂（TKI）被批准作为转移性非小细胞肺癌（NSCLC）的一线治疗药物。在SCLC中，EGFR突变的临床效果及其对奥希替尼的反应尚不清楚。我们报告一例63岁女性EGFR阳性转移性SCLC患者，该患者接受了第三代TKI奥希替尼治疗。
